| NCT03326921 |
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03326921 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2023-12-16 |
| NCT03263572 |
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT03263572 |
Recruiting |
M.D. Anderson Cancer Center |
2023-11-30 |
| NCT03147612 |
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT03147612 |
Recruiting |
M.D. Anderson Cancer Center |
2024-02-08 |
| NCT02782403 |
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT02782403 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-08-31 |
| NCT02730312 |
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02730312 |
Recruiting |
Xencor, Inc. |
2020-08-31 |
| NCT02311998 |
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML |
https://ClinicalTrials.gov/show/NCT02311998 |
Recruiting |
M.D. Anderson Cancer Center |
2021-04-01 |
| NCT02530034 |
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02530034 |
Recruiting |
M.D. Anderson Cancer Center |
2022-01-31 |
| NCT02220985 |
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD |
https://ClinicalTrials.gov/show/NCT02220985 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2025-04-01 |
| NCT02115295 |
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT02115295 |
Recruiting |
M.D. Anderson Cancer Center |
2021-05-19 |
| NCT02091245 |
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML |
https://ClinicalTrials.gov/show/NCT02091245 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2018-02-28 |
| NCT01858740 |
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children |
https://ClinicalTrials.gov/show/NCT01858740 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2022-01-30 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01823198 |
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT01823198 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-06-30 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01498445 |
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) |
https://ClinicalTrials.gov/show/NCT01498445 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-06-30 |
| NCT01428635 |
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy |
https://ClinicalTrials.gov/show/NCT01428635 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-01-31 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01424982 |
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT01424982 |
Recruiting |
M.D. Anderson Cancer Center |
2021-10-31 |
| NCT01368523 |
Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial |
https://ClinicalTrials.gov/show/NCT01368523 |
Completed |
Novartis |
2010-01-31 |
| NCT03878524 |
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
https://ClinicalTrials.gov/show/NCT03878524 |
Recruiting |
OHSU Knight Cancer Institute |
2022-02-27 |
| NCT04282187 |
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT04282187 |
Recruiting |
University of Washington |
2024-11-11 |
| NCT04188405 |
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT04188405 |
Recruiting |
M.D. Anderson Cancer Center |
2024-09-01 |
| NCT03934372 |
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors |
https://ClinicalTrials.gov/show/NCT03934372 |
Recruiting |
Incyte Corporation |
2021-10-31 |
| NCT03895671 |
PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS |
https://ClinicalTrials.gov/show/NCT03895671 |
Recruiting |
Versailles Hospital |
2023-12-01 |
| NCT03842696 |
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT03842696 |
Recruiting |
University of Michigan Rogel Cancer Center |
2024-02-29 |
| NCT03630991 |
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy |
https://ClinicalTrials.gov/show/NCT03630991 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-12-31 |
| NCT03595917 |
ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML |
https://ClinicalTrials.gov/show/NCT03595917 |
Recruiting |
Dana-Farber Cancer Institute |
2021-11-01 |
| NCT03589729 |
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers |
https://ClinicalTrials.gov/show/NCT03589729 |
Recruiting |
M.D. Anderson Cancer Center |
2020-12-31 |
| NCT03576547 |
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT03576547 |
Recruiting |
M.D. Anderson Cancer Center |
2022-01-31 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01204164 |
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01204164 |
Completed |
Tragara Pharmaceuticals, Inc. |
2016-03-31 |
| NCT01126892 |
A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase |
https://ClinicalTrials.gov/show/NCT01126892 |
Completed |
Novartis |
2011-04-30 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT01056614 |
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT01056614 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-08-31 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT00964873 |
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00964873 |
Completed |
Synta Pharmaceuticals Corp. |
2010-12-31 |
| NCT00860574 |
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT00860574 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-02-28 |
| NCT00816283 |
Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT00816283 |
Completed |
City of Hope Medical Center |
2011-06-30 |
| NCT01904136 |
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT01904136 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-04-30 |
| NCT00786812 |
Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase |
https://ClinicalTrials.gov/show/NCT00786812 |
Completed |
Novartis |
2012-01-31 |
| NCT00763763 |
Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive |
https://ClinicalTrials.gov/show/NCT00763763 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2007-10-31 |
| NCT00702403 |
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML |
https://ClinicalTrials.gov/show/NCT00702403 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-12-31 |
| NCT00636909 |
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders |
https://ClinicalTrials.gov/show/NCT00636909 |
Completed |
Beth Israel Deaconess Medical Center |
2006-03-31 |
| NCT00540995 |
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer |
https://ClinicalTrials.gov/show/NCT00540995 |
Active, not recruiting |
City of Hope Medical Center |
2011-12-10 |
| NCT00538109 |
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase |
https://ClinicalTrials.gov/show/NCT00538109 |
Completed |
King Faisal Specialist Hospital & Research Center |
2013-10-31 |
| NCT00514969 |
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase |
https://ClinicalTrials.gov/show/NCT00514969 |
Completed |
University of Bologna |
NA |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00459212 |
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00459212 |
Completed |
National Cancer Institute (NCI) |
2010-12-31 |
| NCT00449761 |
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis) |
https://ClinicalTrials.gov/show/NCT00449761 |
Completed |
Novartis |
2008-08-31 |
| NCT00426205 |
GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT00426205 |
Completed |
Dana-Farber Cancer Institute |
2007-09-30 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00390793 |
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. |
https://ClinicalTrials.gov/show/NCT00390793 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-08-31 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00381550 |
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00381550 |
Completed |
National Cancer Institute (NCI) |
2011-03-31 |
| NCT00357305 |
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00357305 |
Completed |
National Cancer Institute (NCI) |
2011-11-30 |
| NCT00331513 |
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes |
https://ClinicalTrials.gov/show/NCT00331513 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00316953 |
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate |
https://ClinicalTrials.gov/show/NCT00316953 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00309907 |
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00309907 |
Completed |
Children’s Oncology Group |
2011-09-30 |
| NCT00301938 |
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes |
https://ClinicalTrials.gov/show/NCT00301938 |
Completed |
National Cancer Institute (NCI) |
2012-05-31 |
| NCT00278330 |
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia |
https://ClinicalTrials.gov/show/NCT00278330 |
Completed |
National Cancer Institute (NCI) |
2009-10-31 |
| NCT00275080 |
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00275080 |
Completed |
National Cancer Institute (NCI) |
2009-11-30 |
| NCT00258271 |
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00258271 |
Completed |
University of Rochester |
2006-10-31 |
| NCT00217646 |
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00217646 |
Completed |
National Cancer Institute (NCI) |
2010-12-31 |
| NCT00171158 |
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis |
https://ClinicalTrials.gov/show/NCT00171158 |
Completed |
Novartis |
2013-04-30 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00103701 |
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT00103701 |
Completed |
Bristol-Myers Squibb |
2006-03-31 |
| NCT00101816 |
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate |
https://ClinicalTrials.gov/show/NCT00101816 |
Completed |
Bristol-Myers Squibb |
2006-08-31 |
| NCT00098423 |
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes |
https://ClinicalTrials.gov/show/NCT00098423 |
Completed |
National Cancer Institute (NCI) |
2009-05-31 |
| NCT00098826 |
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes |
https://ClinicalTrials.gov/show/NCT00098826 |
Completed |
National Cancer Institute (NCI) |
2008-05-31 |
| NCT00095797 |
XK469R in Treating Patients With Refractory Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00095797 |
Completed |
National Cancer Institute (NCI) |
2007-03-31 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00087204 |
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00087204 |
Completed |
National Cancer Institute (NCI) |
2007-01-31 |
| NCT00084916 |
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase |
https://ClinicalTrials.gov/show/NCT00084916 |
Completed |
National Cancer Institute (NCI) |
2007-03-31 |
| NCT00003997 |
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00003997 |
Completed |
National Cancer Institute (NCI) |
2000-10-31 |
| NCT00081874 |
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00081874 |
Completed |
M.D. Anderson Cancer Center |
2006-09-30 |
| NCT00006475 |
STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis |
https://ClinicalTrials.gov/show/NCT00006475 |
Completed |
Novartis |
2002-12-31 |
| NCT00003735 |
Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00003735 |
Completed |
Children’s Oncology Group |
2002-11-30 |
| NCT00081133 |
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT00081133 |
Completed |
Memorial Sloan Kettering Cancer Center |
2005-02-28 |
| NCT00077467 |
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia |
https://ClinicalTrials.gov/show/NCT00077467 |
Completed |
National Cancer Institute (NCI) |
2006-03-31 |
| NCT00077181 |
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00077181 |
Completed |
National Cancer Institute (NCI) |
2008-07-31 |
| NCT00005064 |
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00005064 |
Completed |
National Cancer Institute (NCI) |
2002-10-31 |
| NCT00006213 |
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00006213 |
Completed |
National Cancer Institute (NCI) |
2002-10-31 |
| NCT00068718 |
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant |
https://ClinicalTrials.gov/show/NCT00068718 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-04-30 |
| NCT00067028 |
Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML |
https://ClinicalTrials.gov/show/NCT00067028 |
Completed |
M.D. Anderson Cancer Center |
2013-06-30 |
| NCT00054431 |
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00054431 |
Completed |
National Cancer Institute (NCI) |
2007-05-31 |
| NCT00053963 |
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT00053963 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00015834 |
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00015834 |
Completed |
National Cancer Institute (NCI) |
2003-04-30 |
| NCT00012376 |
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer |
https://ClinicalTrials.gov/show/NCT00012376 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00042003 |
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) |
https://ClinicalTrials.gov/show/NCT00042003 |
Completed |
Astex Pharmaceuticals, Inc. |
2004-12-31 |
| NCT00034684 |
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) |
https://ClinicalTrials.gov/show/NCT00034684 |
Completed |
Merck Sharp & Dohme Corp. |
2003-10-31 |
| NCT00111683 |
MK0457 in Patients With Leukemia (0457-003) |
https://ClinicalTrials.gov/show/NCT00111683 |
Completed |
Merck Sharp & Dohme Corp. |
2008-05-31 |
| NCT00105001 |
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00105001 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-05-31 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00101595 |
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT00101595 |
Completed |
Bristol-Myers Squibb |
2007-12-31 |